RT Journal Article
SR Electronic
T1 Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00056-2023
DO 10.1183/23120541.00056-2023
VO 9
IS 6
A1 Domingo, Christian
A1 Rabe, Klaus F.
A1 Price, David
A1 Brusselle, Guy
A1 Wechsler, Michael E.
A1 Xia, Changming
A1 Pandit-Abid, Nami
A1 Gall, Rebecca
A1 Rowe, Paul J.
A1 Deniz, Yamo
A1 Jacob-Nara, Juby A.
A1 Radwan, Amr
YR 2023
UL http://openres.ersjournals.com/content/9/6/00056-2023.abstract
AB Background Dupilumab has been shown to improve clinical outcomes long term while reducing oral corticosteroid (OCS) dose in patients with severe OCS-dependent asthma. This post hoc analysis assesses the impact of OCS dose at baseline (≤10 or >10 mg·day−1) on long-term outcomes of dupilumab treatment.Methods Annualised severe asthma exacerbation rates, forced expiratory volume in 1 s (FEV1), measures of asthma control and quality of life, and OCS dose were evaluated in patients from the phase 3 VENTURE trial with severe OCS-dependent asthma, further categorised by OCS dose ≤10 or >10 mg·day−1 at parent study baseline (PSBL), who enrolled in TRAVERSE.Results Dupilumab reduced the annualised exacerbation rate in VENTURE, and it remained low throughout TRAVERSE (0.202–0.265 (OCS ≤10 mg·day−1 at PSBL) and 0.221–0.366 (OCS >10 mg·day−1 at PSBL)). Improvements in pre-bronchodilator FEV1, asthma control and quality of life observed in VENTURE dupilumab patients were sustained throughout TRAVERSE. Patients on placebo during VENTURE showed rapid improvements in FEV1 upon initiating dupilumab in TRAVERSE, which were sustained to the end of TRAVERSE. Reductions in OCS dose observed in VENTURE were maintained throughout TRAVERSE, with more than two-thirds of patients achieving reductions in OCS doses to ≤5 mg·day−1 by TRAVERSE week 48.Conclusions Improvements in clinical outcomes and reductions in OCS dose with dupilumab observed in VENTURE were maintained throughout TRAVERSE, regardless of baseline disease severity. Patients who switched from placebo in VENTURE to dupilumab in TRAVERSE had improved clinical outcomes and reductions in OCS dose comparable to those given dupilumab in VENTURE.Long-term treatment with dupilumab reduces asthma exacerbations, improves lung function, symptom control and quality of life, and reduces oral corticosteroid (OCS) use in patients with OCS-dependent asthma regardless of baseline OCS dose. https://bit.ly/44A7m1k